Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration
Top Cited Papers
Open Access
- 1 January 2018
- journal article
- research article
- Published by Elsevier BV in Ophthalmology Retina
- Vol. 2 (1), 24-30
- https://doi.org/10.1016/j.oret.2017.03.015
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Predicting the Future — Big Data, Machine Learning, and Clinical MedicineThe New England Journal of Medicine, 2016
- Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW TrialsOphthalmology, 2016
- A paradigm shift in imaging biomarkers in neovascular age-related macular degenerationProgress in Retinal and Eye Research, 2016
- Automated segmentation of geographic atrophy of the retinal epithelium via random forests in AREDS color fundus imagesComputers in Biology and Medicine, 2015
- Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)British Journal of Ophthalmology, 2014
- Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments TrialsOphthalmology, 2013
- Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular DegenerationOphthalmology, 2013
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2011
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006